TABLE 3.
Multivariate analysis of survival
| Prognostic factors | n | Locoregional control | Disease free survival | Disease specific survival | Overall survival |
|---|---|---|---|---|---|
|
| |||||
| p | p | p | p | ||
| pT- stage | |||||
| pT 1+2 | 48 | ||||
| pT 3+4 | 75 | 0.03 | |||
| pN- stage | |||||
| pN 0+1+2 | 98 | ||||
| pN 3 | 25 | ||||
| Overall stage | |||||
| Stage Ib –III | 93 | ||||
| Stage IV | 30 | 0.05 | |||
| Stomach involvement | |||||
| Whole stomach | 7 | ||||
| Individual areas | 116 | ||||
| Primary tumour site | |||||
| Cardia | 16 | ||||
| Other sites | 107 | ||||
| Perineurial invasion | |||||
| Yes | 45 | ||||
| No | 59 | ||||
| Angioinvasion | |||||
| Yes | 45 | 0.07 | |||
| No | 23 | ||||
| Initial Hb level | |||||
| Hb start ≤ 110 g/l | 24 | ||||
| Hb start > 110 g/l | 99 | 0.009 | 0.0001 | 0.02 | 0.01 |
| 5-FU total dose per cycle | |||||
| ≤ 4000 mg | 109 | ||||
| > 4000 mg | 14 | 0.03 | 0.07 | ||
pT = pathological T-stage; pN = pathological N-stage; Hb start = haemoglobin concentration at the start of the therapy